NEW YORK (GenomeWeb News) – Sigma-Aldrich and Oxford BioMedica said today that they have settled their two-year-old litigation with Open Biosystems over patents covering lentiviral vector technology.
Sigma-Aldrich and Oxford agreed to dismiss their suit against Open Bio, and Open Bio agreed to dismiss its counterclaims. As part of the settlement, Open Bio will acquire certain licensing rights to patents covering the use of Oxford’s LentiVector technology in research activities.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.